Skip to main content
. Author manuscript; available in PMC: 2020 Jan 24.
Published in final edited form as: Pharmacogenomics J. 2019 Feb 4;19(6):528–537. doi: 10.1038/s41397-019-0076-2

Figure 4. Provider Change in Self-Reported Knowledge of Pharmacogenomics During Implementation.

Figure 4.

Two provider repeated interval surveys from each of the study providers were included in this analysis—the baseline survey (prior to availability of the Genomic Prescribing System [GPS] for clinical use) and the last completed survey (after each provider had access to GPS for at least 6 months). At baseline, 61.1% of providers reported feeling at least somewhat informed about pharmacogenomics. When asked the same question post-study participation, 94.4% of providers felt at least somewhat informed (p=0.04). For statistical purposes, “very well-informed” and “somewhat informed” were combined and compared to the combined “somewhat under-informed” and “very under-informed” using McNemar’s test.

*Each provider completed a baseline repeated interval survey and ≥1 post-GPS implementation repeated interval survey. Out of 106 total surveys distributed, 76 (71.7%) were returned (median surveys returned/provider: 4, range 2–8).